Delivery Order SPE2DB22D2206-SPE2DB25FKA35
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on September 2, 2025, with a ceiling value of $23,791.44 and firm fixed pricing. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $11,895.72 to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count packaging) on September 11, 2025, with an ultimate completion date of October 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) for INLYTA 5 mg tablets (60-count) on July 25, 2025. The contract is a firm fixed-price delivery order with a ceiling value of $11,895.72 and an ultimate completion date of August 15, 2025. This award was made through open competition with no set-aside designation and represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,791.44 delivery order to AmerisourceBergen Drug Corp for 60 tablets of INLYTA 5 mg on September 18, 2025, with an ultimate completion date of October 9, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Inlyta 5 mg tablets (60-count units). This is a firm fixed-price, non-set-aside contract with a completion date of September 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Inlyta is a prescription medication used in oncology treatment, reflecting the federal government's ongoing pharmaceutical supply...
- The Defense Logistics Agency awarded a $23,847.20 delivery order to AmerisourceBergen Drug Corp for 180 tablets of INLYTA 1 mg, a pharmaceutical product used in cancer treatment. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $71,374.32 to supply 60 tablets of INLYTA 5 mg, a pharmaceutical product, with performance at the company's Conshohocken, Pennsylvania facility. The award, issued on September 12, 2025, carries a completion date of October 3, 2025, and utilizes firm fixed pricing without any set-aside designation. This delivery order represents a competitive award to the prime contractor under an existing contract vehicle....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $11,895.72 by the Defense Logistics Agency on July 22, 2025, for the supply of INLYTA 5 mg tablets in quantities of 60 units. The contract, which carries a firm fixed-price structure with an ultimate completion date of August 12, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $11,895.72 delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $23,847.20 firm fixed price delivery order to AmerisourceBergen Drug Corp for 180 tablets of Inlyta 1 mg, a pharmaceutical product for oncology treatment. This non-set-aside delivery order was competitively awarded on August 15, 2025, with an ultimate completion date of September 8, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKA35Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, for 180 tablets of Inlyta 1 mg on September 22, 2025, with a ceiling value of $23,847.20 and completion date of October 14, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. Inlyta (axitinib) is a prescription oncology medication used in the treatment of advanced renal cell carcinoma, indicating this procurement supports military healthcare pharmaceutical needs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare systems. The company's track record demonstrates consistent capability to fulfill federal medical procurement requirements through open competition, with delivery orders typically utilizing firm fixed pricing across a wide range of therapeutic domains. This delivery order exemplifies the company's role as a key supplier within the DLA's pharmaceutical supply chain serving military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 9/22/25 |